| Document |
Document Title |
|
WO/2023/076404A1 |
Provided is a method for treating systemic lupus erythematosus (SLE) in a patient in need thereof comprising administering a therapeutically effective amount of a leucine-rich repeat kinase 2 (LRRK2) inhibitor.
|
|
WO/2023/072284A1 |
The present invention relates to a class of gonadotropin-releasing hormone antagonists, which have antagonistic activity to gonadotropin-releasing hormone and can be used for preventing or treating sex hormone-dependent diseases, such as...
|
|
WO/2023/072878A1 |
The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated bea...
|
|
WO/2023/066357A1 |
The present disclosure relates to fused cyclic compounds, preparation methods therefor, and medical uses thereof. Specifically, the present disclosure relates to the fused cyclic compound represented by general formula (I), a preparation...
|
|
WO/2023/065684A1 |
The present disclosure provides an application of sodium caprylate in the preparation of a drug for improving a cardio-pulmonary resuscitation effect and multiple organ dysfunction syndrome after cardio-pulmonary resuscitation, relating ...
|
|
WO/2023/066348A1 |
Provided are a new compound as represented by formula (I) having a dual antagonistic effect of an angiotensin II receptor and an endothelin receptor, and the use thereof in the preparation of a drug.
|
|
WO/2023/065439A1 |
The present invention relates to the cross-technical fields of medicine, material chemistry, glycobiology and the like, in particular to a sulfonated hyaluronic acid compound, a preparation method therefor and an application thereof. The...
|
|
WO/2023/070069A1 |
Provided herein are methods of using modified caveolin-1 (Cav-1) peptides to treat or prevent a kidney disease or disorder in a subject. In particular, provided are methods of using the modified Cav-1 peptides for the treatment of chroni...
|
|
WO/2023/066834A1 |
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions contai...
|
|
WO/2023/066359A1 |
It provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. It also provides methods for treating LPA-associated diseases, disorders, and conditions.
|
|
WO/2023/065833A1 |
An oxygen capsulate, a preparation method therefor comprising the following steps: carrying out three-stage separation on deodorized cocoa butter, then carrying out mixing treatment on negative oxygen ions and deodorized cocoa butter liq...
|
|
WO/2023/068366A1 |
The present invention addresses mainly the problem of providing a novel composition or pharmaceutical that targets the mitochondrial network etc. and exhibits excellent anticancer activity while having a minimal effect on normal cells.ã€...
|
|
WO/2023/066127A1 |
The present invention provides a use of an NK3R inhibitor in preparation of a drug, the drug is used for treating chronic kidney diseases, and the structure of the NK3R inhibitor is as shown in formula (I) or formula (II).
|
|
WO/2023/063851A1 |
This invention relates to organic chemistry, pharmacology, medicine, namely the invention relates to compounds for use in inhibiting the activity of human cytochrome 11B2 (CYP11B2) and their use in the treatment and/or prevention of vari...
|
|
WO/2023/061438A1 |
A pharmaceutical composition and the use thereof. The composition contains silodosin and Finasteride as active components. Use of the composition in the preparation of a drug for inhibiting the contraction of prostate smooth muscle or in...
|
|
WO/2023/062638A1 |
The invention relates to a biphasic composition for instillation into a body cavity, such as the urinary bladder, or kidney for delivering an active agent comprising Phase A, wherein Phase A is a hydrophilic hydrogel; and Phase B, is a l...
|
|
WO/2023/064925A1 |
Use of an autologous e.g., selected, renal cell therapeutic for improving kidney function of a human patient having diabetic chronic kidney disease is provided herein. The use of the therapeutic, administered in first and second injectio...
|
|
WO/2023/063400A1 |
Provided is a transgenic non-human animal enabling an analysis of an evaluation of proteasome function and activity on an individual basis. The present invention relates to a transgenic non-human animal and the like with an attenuated pr...
|
|
WO/2023/064768A1 |
G protein-coupled receptor (GPCR) regulators and methods for their use are provided herein. The GPCR regulators described herein are useful in treating and/or preventing conditions or diseases associated with a GPCR, including ageing, ca...
|
|
WO/2023/064257A1 |
Described herein are methods for treating hyperoxaluria in a subject with Compound 1, represented by the formula: (Compound 1), a tautomer, a pharmaceutically acceptable salt, a hydrate, a solvate, or a combination thereof. In particular...
|
|
WO/2023/063242A1 |
One purpose of the present invention is to provide an autoimmune disease therapeutic agent that can selectively inhibit IFN-γ, does not have a risk of biological contamination, and can be stored at room temperature. Provided is an autoi...
|
|
WO/2023/058022A1 |
This invention, in some embodiments thereof, provides a core- shell nanoparticle including a lipid-PSMA conjugate, encapsulating a liquid oil-based core. The invention further provides aqueous compositions including the core-shell nanopa...
|
|
WO/2023/060237A1 |
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
|
|
WO/2023/059188A1 |
The invention relates to a distinct and newly emerging class of drugs: peptide modulators of mTOR that act as autophagy inhibiting compounds and target the nutrient sensing system of the mechanistic target of rapamycine (mTOR) and induce...
|
|
WO/2023/060190A1 |
Disclosed herein are nephron progenitor extracellular vesicles (EVs) that can be used to treat acute kidney injury and methods of using same. For example, disclosed herein is a composition involving nephron progenitor extracellular vesic...
|
|
WO/2023/054712A1 |
The present invention pertains to a peptide and a composition containing the peptide. The peptide according to the present invention has an amino acid sequence F-Nal1-V-V-N-V-Y-D-D-PeG-V-Nal1-Y-H-V-C-G (SEQ ID NO. 2) or has an amino acid...
|
|
WO/2023/053715A1 |
Provided is a composition comprising Chlamydomonas reinhardtii or an extract of the Chlamydomonas reinhardtii, wherein the Chlamydomonas reinhardtii or the extract of the Chlamydomonas reinhardtii functions as an antagonist of an adrener...
|
|
WO/2023/055920A1 |
The present disclosure relates to pharmaceutical compounds of the Formula (I), (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt or composition thereof. Also provided are methods of use of TRPML modulators for treating disorders,...
|
|
WO/2023/055912A1 |
The present disclosure relates to pharmaceutical compounds of the Formulas I, Ia, Ib, or Ic or a pharmaceutically acceptable salt or composition thereof. Also provided are methods of use of TRPML modulators for treating disorders, the mo...
|
|
WO/2023/055686A1 |
Provided herein are LpxC inhibitor compounds, as well as pharmaceutical compositions comprising said compounds, and methods of use thereof in the treatment of disease that would benefit from treatment with an LpxC inhibitor, including gr...
|
|
WO/2023/055827A1 |
Described herein are compounds that are parathyroid hormone (PTH) receptor modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the tr...
|
|
WO/2023/054825A1 |
The present invention relates to a culture medium for isolating and culturing urine-derived stem cells, a method for isolating and culturing urine-derived stem cells using the culture medium, urine-derived stem cells cultured in the cult...
|
|
WO/2023/051793A1 |
Disclosed are a compound as an inhibitor of complement factor D, and a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a compound as represented by formula (I), a tautomer thereof, a stereoisomer thereo...
|
|
WO/2023/046664A1 |
The invention relates to novel compounds of the general formula (l-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
|
WO/2023/049860A1 |
The present disclosure relates generally to dis-arming immune cell product sensitivity to androgens. Provided herein are methods, systems, and compositions for disarming androgen receptor (AR) activity in immune cells, for instance in th...
|
|
WO/2023/045005A1 |
The present invention relates to a method for preparing total glucosides of Paeonia. The method comprises the following steps: 1) extraction: taking decoction pieces of radix paeoniae alba, extracting with ethanol, and filtering an extra...
|
|
WO/2023/049121A1 |
Analysis of gene expression in allograft biopsies is provided for diagnosis and/or treatment of antibody rejection. We chose over a hundred candidate genes to evaluate their association with allograft pathology by real-time quantitative ...
|
|
WO/2023/049787A1 |
The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing a kidney disease, and methods of identifying subjects having an increased risk of developing a kidney disease.
|
|
WO/2023/046046A1 |
Provided is a hydrogenation synthesis method for preparing a pyrazinecarboxylic acid derivative as a fluorescent tracer, in particular, provided is a method for preparing 3,6-diamino-2,5-bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamo
yl}py...
|
|
WO/2023/045360A1 |
The present invention relates to the technical field of drug synthesis. Disclosed are a crystal form of a macrocyclic compound, and a preparation method therefor and the use thereof. The macrocyclic compound is (6R, 16R)-9-fluoro-16-meth...
|
|
WO/2023/048277A1 |
Provided is a group 2 innate lymphoid cell growth inhibitor containing MAIT cells.
|
|
WO/2023/049917A1 |
The present disclosure encompasses novel anti- TGFβ1,2,3 antibodies and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies and/or nucleotide of the 5 invention for the treatment and/or prevent...
|
|
WO/2023/039947A1 |
Disclosed are a pharmaceutical composition containing cefoperazone sodium and tazobactam sodium, and an application thereof. In the pharmaceutical composition, the weight ratio of cefoperazone sodium to tazobactam sodium is 6:1. In the t...
|
|
WO/2023/044326A1 |
The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl
)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of usin...
|
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
|
WO/2023/042996A1 |
The present invention relates to a pharmaceutical composition for preventing or treating focal segmental glomerulosclerosis acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutica...
|
|
WO/2023/043024A1 |
The present invention relates to a pharmaceutical composition for preventing or treating Interstitial Fibrosis and Tubular Atrophy (IFTA) acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a...
|
|
WO/2023/043473A1 |
A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human TGF-β. In certain aspects, the disclosed invention is based, on engineering of a heterodimer...
|
|
WO/2023/039500A1 |
The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and/or prevention of stress urinary incontinence [SUI | and fecal incontinence [FI] due to weakness...
|
|
WO/2023/039063A1 |
The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,
2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
|
